Trials / Unknown
UnknownNCT06154343
A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
A Phase 1, First-In-Human, Multicenter, Open-Label,Dose-Escalation and Extension Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GQ1005 | an antibody drug conjugate |
Timeline
- Start date
- 2022-11-23
- Primary completion
- 2024-12-31
- Completion
- 2025-07-30
- First posted
- 2023-12-04
- Last updated
- 2023-12-04
Locations
20 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06154343. Inclusion in this directory is not an endorsement.